Activity of LBM415 compared to those of 11 other agents against Haemophilus species

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 7, 2006, Pages 2323-2329

  Bogdanovich, Tatiana ^a   Smith, Kathy A ^a   Clark, Catherine ^a   Pankuch, Glenn A ^a   Lin, Gengrong ^a   McGhee, Pamela ^a   Dewasse, Bonifacio ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFDINIR; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DEFORMYLASE; ERYTHROMYCIN; FORMYLTRANSFERASE; GATIFLOXACIN; GEMIFLOXACIN; GENE PRODUCT; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PEPTIDE DEFORMYLASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DEF GENE; DRUG POTENCY; FMT GENE; GENE; GENE MUTATION; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; SELECTION (GENETICS);

EID: 33745584415     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00106-06     Document Type: Article

References (32)

1. Anderegg, T. R., D. J. Biedenbach, R. N. Jones, and the Quality Control Working Group. 2003. Quality control guidelines for MIC susceptibility testing of NVP-PDF713, a novel peptide deformylase inhibitor. Int. J. Antimicrob. Agents 22:84-86.
2. Bastida, T., M. Pérez-Vazquez, J. Campos, M. C. Cortés-Lietget, F. Roman, F. Tubau, A. G. de la Campa, and C. Alonso-Tarrés. 2003. Levofloxacin treatment failure in Haemophilus influenzae pneumonia. Emerg. Infect. Dis. 9:1475-1478.
3. Clark, C., B. Bozdogan, M. Peric, B. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2002. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. Antimicrob. Agents Chemother. 46:2956-2962.
4. Clements, J. M., R. P. Beckett, A. Brown, G. Gatlin, M. Lobell, S. Palan, W. Thomas, M. Whittaker, S. Wood, S. Salama, P. J. Baker, H. F. Rodgers, V. Barynin, D. W. Rice, and M. G. Hunter. 2001. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 45:563-570.
5. Craig, W. A., and S. Gudmondsson. 1996. Postantibiotic effect, p. 265-329. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams and Wilkins Co., Baltimore, Md.
6. Credito, K. L., G. Lin, G. A. Pankuch, S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 2001. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob. Agents Chemother. 45:67-72.
7. Credito, K., G. Lin, L. M. Ednie, and P. C. Appelbaum. 2004. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared to other agents. Antimicrob. Agents Chemother. 48:4033-4036.
8. Dabernat, H., C. Delmas, M. Seguy, R. Pelissier, G. Faucon, S. Bennamani, and C. Pasquier. 2002. Diversity of β-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob. Agents Chemother. 46:2208-2218.
9. Daines, D. A., L. A. Cohn, H. N. Coleman, K. S. Kim, and A. L. Smith. 2003. Haemophilus influenzae Rd KW20 has virulence properties. J. Med. Microbiol. 52:277-282.
10. Davies, T. A., L. M. Kelly, D. B. Hoellman, L. M. Ednie, C. K. Clark, S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 2000. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 44:633-639.
11. Dean, C. R., S. Narayan, D. M. Daigle, J. L. Dzink-Fox, X. Puyang, K. R. Bracken, K. E. Dean, B. Weidmann, Z. Yuan, R. Jain, and N. S. Ryder. 2005. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob. Agents Chemother. 49:3129-3135.
12. Edelstein, P. H., B. Hu, and M. A. C. Edelstein. 2005. In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila. Antimicrob. Agents Chemother. 49:2533-2535.
13. Ednie, L. M., G. Pankuch, and P. C. Appelbaum. 2004. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor compared to other agents. Antimicrob. Agents Chemother. 48:4027-4032.
14. Fritsche, T. R., G. J. Moet, and R. N. Jones. 2004. Commercial broth microdilution panel validation and reproducibility trials for NVP-PDF 713 (LBM 415), a novel inhibitor of bacterial peptide deformylase. Clin. Microbiol. Infect. 10:857-860.
15. Fritsche, T. R., H. S. Sader, R. Cleeland, and R. N. Jones. 2005. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 49:1468-1476.
16. Goldstein, F. W., M. E. Emiran, A. Coutrot, and J. F. Acar. 1990. Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. J. Antimicrob. Chemother. 25(Suppl. A):25-28.
17. Jacobs, M. R., S. Bajaksouzian, A. Zilles, G. Lin, G. A. Pankuch, and P. C. Appelbaum. 1999. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 USA surveillance study. Antimicrob. Agents Chemother. 43:1901-1908.
18. Jacobs, M. R. 2001. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect. 7:589-596.
19. Jones, R. N., T. R. Fritsche, and H. S. Sader. 2004. Antimicrobial spectrum and activity of NVP-PDF 713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49:63-65.
20. Jones, R. N., G. J. Moet, H. S. Sader, and T. R. Fritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP-PDF 713) against oxazolidinone-resistant or streptogramin-resistant gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.
21. Kosowska, K., K. Credito, G. A. Pankuch, D. Hoellman, G. Lin, C. Clark, B. Dewasse, P. McGhee, M. R. Jacobs, and P. C. Appelbaum. 2004. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Antimicrob. Agents Chemother. 48:4113-4119.
22. Margolis, P., C. Hackbarth, S. Lopez, M. Maniar, W. Wang, Z. Yuan, R. White, and J. Trias. 2001. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. 45:2432-2435.
23. Marrs, C. F., G. P. Krasan, K. W. McCrea, D. L. Clemans, and J. R. Gilsdorf. 2001. Haemophilus influenzae-human specific bacteria. Front. Biosci. 6:E41-E60.
24. Maskell, J. P., A. M. Sefton, and J. D. Williams. 1990. Comparative in-vitro activity of azithromycin and erythromycin against gram-positive cocci, Haemophilus influenzae and anaerobes. J. Antimicrob. Chemother. 25(Suppl. A):19-24.
25. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Nazir, J., C. Urban, N. Mariano, J. Burns, B. Tommasulo, C. Rosenberg, S. Segal-Mayrer, and J. J. Rahal. 2004. Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin. Infect. Dis. 38:1564-1569.
27. Needham, C. A. 1988. Haemophilus influenzae antibiotic susceptibility. Clin. Microbiol. Rev. 1:218-227.
28. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
29. Peric, M., B. Bozdogan, M. R. Jacobs, and P. C. Appelbaum. 2003. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob. Agents Chemother. 47:1017-1022.
30. Schito, A. M., G. C. Schito, E. Debbia, G. Russo, J. Linares, E. Cercenado, and E. J. Bouza. 2003. Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000. J. Chemother. 15:226-234.
31. Tristram, S. G., B. Bozdogan, and P. C. Appelbaum. 2005. Disc diffusion-based screening tests for extended-spectrum β-lactamases in Haemophilus influenzae. J. Antimicrob. Chemother. 55:570-573.
32. Waites, K. B., N. P. Reddy, D. M. Crabb, and L. B. Duffy. 2005. Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 49:2541-2542.